GE MEDICAL SYSTEMS

Lantheus Holdings and GE HealthCare announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize piflufolastat F18 (PYLARIFY) in Japan for prostate cancer diagnostics.

GE HealthCare has acquired brain analysis company Icometrix for an undisclosed sum to expand its Alzheimer's disease diagnostic capabilities.

GE HealthCare received FDA 510(k) clearance for its Revolution Vibe CT system, designed to address challenging cardiac exams including patients with arrhythmias and heavily calcified coronaries.

Bayer has submitted marketing authorization applications for gadoquatrane, an investigational MRI contrast agent that delivers 60% lower gadolinium dosing compared to standard agents while maintaining diagnostic efficacy.

The FDA has expanded approval for GE HealthCare's Optison, allowing the ultrasound enhancing agent to be used in pediatric patients with suboptimal echocardiograms, following successful Phase IV clinical trials.

GE HealthCare has received FDA 510(k) clearance for its Aurora nuclear medicine system and Clarify DL, with University Hospitals in Cleveland becoming the first U.S. institution to adopt this technology.

Turing Medical has appointed Kevin King, former CEO of iRhythm Technologies, as its new President and Chief Executive Officer to accelerate the company's expansion in precision brain mapping technology.

• Johnson & Johnson's Monarch Quest software update received FDA 510(k) clearance, boosting computational power by 260% to improve accuracy in reaching suspicious lung nodules. • The enhanced robotic platform integrates Nvidia's AI technology and GE Healthcare's OEC 3D mobile imaging system to navigate complex patient airways for more precise early-stage lung cancer diagnosis. • This advancement addresses a critical need in lung cancer detection, as nearly half of early-stage lesions occur in peripheral lung areas that are difficult to access with traditional bronchoscopy methods.

GE HealthCare has successfully administered the first doses of Flyrcado, an FDA-approved PET imaging agent for coronary artery disease detection, at Houston Methodist Hospital.

SmartMammo Dx, an AI algorithm by DeepHealth, secured FDA clearance for use with GE HealthCare's Senographe Pristina mammography systems.